Clinical characterization and prognostic factors of primary lymphoma of bone in case of Chinese patients

被引:5
作者
Jia-Jia Huang
Yi Xia
Ying-Jie Zhu
Tong-Yu Lin
Zhi-Ming Li
Wen-Qi Jiang
Rui-Hua Xu
Hui-Qiang Huang
Yue Lv
Xiao-Fei Sun
Zhong-Jun Xia
机构
[1] Sun Yat-sen University,State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Cancer Center
来源
Medical Oncology | 2011年 / 28卷
关键词
Primary lymphoma of the bone; Clinical characterization; Prognostic factors; Rituximab; Bisphosphonates;
D O I
暂无
中图分类号
学科分类号
摘要
Primary lymphoma of bone (PLB) is a very rare neoplasm. Many aspects of this entity have not been well defined or reported in Chinese population. The purpose of our study is to identify the prognostic factors of PLB. Twenty-five patients newly diagnosed with PLB were included in this retrospective study. The main pathologic subtype of PLB was diffuse large B-cell lymphoma (DLBCL), followed by anaplastic large-cell lymphoma. The pelvis was the most commonly involved site (13 cases, 52%). The 5-year overall survival (OS) rate was 55.0%. Cox regression analysis demonstrated that IPI score was an independent prognostic factor of survival (RR = 8.46, P = 0.013). The mean survival time (MST) was 90.3 months for patients with radiation and 54.0 months for those without radiotherapy (P = 0.033). Patients who received the anti-CD20 monoclonal antibody rituximab therapy showed a favorable survival trend, but not significant benefit (MST: 74.5 months vs. 68.6 months, P = 0.149). Some clinical characteristics in the Chinese population are different from those in westerners. The frequency of T-cell subtypes is higher, and the pelvis is the most commonly involved site. Irradiation plus chemotherapy may be better than chemotherapy alone. The role of bisphosphonates and rituximab in PLB therapy warrants further investigation.
引用
收藏
页码:476 / 482
页数:6
相关论文
共 97 条
[1]  
Dubey P(1997)Localized primary malignant lymphoma of bone Int J Radiat Oncol Biol Phys 37 1087-1093
[2]  
Ha CS(2007)A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency Ann Oncol 18 129-135
[3]  
Besa PC(1994)Bone presentation of non-Hodgkin’s lymphoma: experience at the Royal North Shore Hospital, Sydney; highlighting primary bone lymphoma Aust N Z J Med 24 701-704
[4]  
Fuller L(1997)Primary extranodal non-Hodgkin’s lymphomas. Part 1: gastrointestinal, cutaneous and genitourinary lymphomas Ann Oncol 8 727-737
[5]  
Cabanillas F(2006)Primary non-Hodgkin’s lymphoma of bone: a rare disorder with high frequency of T-cell phenotype in southern Taiwan Leuk Lymphoma 47 65-70
[6]  
Murray J(2005)Primary multifocal osseous Hodgkin disease: a case report and review of the literature J Cancer Res Clin Oncol 131 163-168
[7]  
Ramadan KM(1999)Osseous Hodgkin disease Cancer 85 1166-1178
[8]  
Shenkier T(2010)Primary bone lymphoma–the University of Miami experience Leuk Lymphoma 51 39-49
[9]  
Sehn LH(2008)Primary bone lymphoma: single institution case series Ir J Med Sci 177 247-251
[10]  
Gascoyne RD(2007)Revised response criteria for malignant lymphoma J Clin Oncol 25 579-586